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Abstract
Background: Epidermal growth factor (EGF), latrophilin and seven transmembrane domain-containing protein 1 (ELTD1) is
developmentally upregulated in the heart. Little is known about the relationship between ELTD1 and cardiac diseases.
Therefore, we aimed to clarify the role of ELTD1 in pressure overload–induced cardiac hypertrophy.
Methods and Results: C57BL/6J wild-type (WT) mice and ELTD1-knockout (KO) mice were subjected to left ventricular
pressure overload by descending aortic banding (AB). KO mice exhibited more unfavorable cardiac remodeling than WT
mice 28 days post AB; this remodeling was characterized by aggravated cardiomyocyte hypertrophy, thickening of the
ventricular walls, dilated chambers, increased fibrosis, and blunted systolic and diastolic cardiac function. Analysis of
signaling pathways revealed enhanced extracellular signal-regulated kinase (ERK) and the c-Jun amino-terminal kinase (JNK)
phosphorylation in response to ELTD1 deletion.
Conclusions: ELTD1 deficiency exacerbates cardiac hypertrophy and cardiac function induced by AB-induced pressure
overload by promoting both cardiomyocyte hypertrophy and cardiac fibrosis. These effects are suggested to originate from
the activation of the ERK and JNK pathways, suggesting that ELTD1 is a potential target for therapies that prevent the
development of cardiac disease.
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Introduction
Cardiac hypertrophy, an increase in heart mass, reflects a
remodeling process in various cardiac diseases [1]. The initial
stage of cardiac hypertrophy is an adaptive process; however,
sustained hemodynamic overload leads to uncompensated hyper-
trophy associated with increased interstitial fibrosis and impaired
cardiac dysfunction; and this uncompensated hypertrophy repre-
sents one of the major risk factors for heart failure. Initiating
stimuli are sensed through an array of membrane-bound G-
protein-coupled receptors (GPCRs) and regulate remodeling by
various signaling pathways. Mitogen-activated protein kinases
(MAPKs), along with phosphoinositide 3-kinase (PI3K) – Akt are
well-studied family of proteins that play an integral role in these
signaling events [2,3]. However, the mechanisms through which
hypertrophy eventually leads to heart failure remain poorly
understood.
ELTD1 is composed of an extracellular domain with epidermal
growth factor (EGF)-like repeats and a seven-transmembrane
domain (TMD7) followed by a short cytoplasmic tail [4]. The
mRNA level of ELTD1 is up regulated postnatally both in rats and
human hearts [4]. The growth of heart is contributed mainly to
proliferation of cardiomyocytes in the initial stage and hypertro-
phy of cardiomyocytes accompanied by remodeling of the
nonmyocyte in mature myocardium. The up-regulation of ELTD1
expression in rat and human hearts couples with the switch of
myocardium from hyperplastic to hypertrophic growth [4]
,suggesting ELTD1 to be an important effector in this process.
Furthermore, the extracellular domain of rat ELTD1 possesses
several common protein kinase phosphorylation sites, and the
short cytoplasmic tail carries a tyrosine kinase phosphorylation site
that could couple to a tyrosine kinase signaling pathway [4]. The
putative phosphorylation site could play a part in signal
transductions employing tyrosine kinases such as MAPKs pathway
[5] and serve as a scaffold for the phosphotyrosine-dependent
complex [6]. The overall structure of ETLD1 suggests that the
protein might participate in both cell surface events such as cell-
cell interaction and in signaling cascades in cardiac development.
However, no research has been conducted on the role of ELTD1
in cardiac diseases using animal models to date [4]. Therefore, the
aims of this study were to determine if deletion of the ELTD1 gene
affects pressure overload-induced cardiac hypertrophy and to
identify the processes that underlie ELTD1-related differences in
the hypertrophic growth response.
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Animals and Aortic Banding
All animal experimental protocols were approved by the
Animal Care and Use Committee of Renmin Hospital of
Wuhan University(protocol number: 00022980), and the proto-
cols were performed in accordance with the Guide for the Care
and Use of Laboratory Animals published by the US National
Institutes of Health (NIH Publication No. 85–23, revised 1996).
C57BL/6 (WT) mice and ELTD1 knockout (KO) mice
(C57BL/6J background) were provided by the European Mouse
Mutant Archive. Their genotypes were confirmed by PCR (data
not shown). The KO mice were viable and showed normal
atrial and ventricular morphology and a normal heart rate,
systolic pressure, contractility (+dP/dt), and relaxation (2dP/dt)
at baseline (data not shown). KO and WT male mice, aged
between 8 and 10 weeks, were randomly assigned to thoracic
aortic banding (AB) group or sham group respectively, and the
numbers of mice are 15,15,20,25 in WT-Sham, KO-Sham,
WT-AB, and KO-AB groups respectively. AB surgeries are
conducted as previously described [7]. Briefly, mice were
anesthetized with pentobarbital sodium (90 mg/kg, i.p.) and
ventilated with room air using a small animal ventilator (model
VFA-23-BV, Kent Scientific, USA). Mice were kept warm on a
heating pad until they regained consciousness. After conducting
a thoracotomy in the second or third intercostal, the descending
aortic was ligated by tying a 7–0 silk suture against a 26-gauge
needle. The same procedure was used for the sham operation
without ligation of the aorta.
Human Ventricular Samples
We analyzed the protein level of ELTD1 of myocardial
samples taken from failing human hearts and healthy controls.
Of these, samples from 4 failing hearts were prepared during
orthotropic heart transplantation representing myocardium from
end-stage heart failure patients (NYHA IV).The failing hearts
were developed from dilated-hypokinetic evolution of hypertro-
phic cardiomyopathy, and is characterized by cavity dilation
and increase of heart mass (data not shown). All patients had no
signs of familial etiology. Control samples were obtained from
the left ventricles of the 4 normal heart donors. After extraction
of the heart, samples were immediately frozen in liquid nitrogen
and stored at 280uC until their processing. The protocols were
reviewed by the local Ethical Committee (Renmin Hospital of
Wuhan University Human Research Ethics Committee, Wuhan,
China), and the experiments were conducted in accordance with
the Tri-Council Policy Statement: Ethical Conduct for Research
Involving Humans. Informed written consent was obtained from
all subjects.
Histological Analysis
The hearts were harvested and randomly assigned for bio-
molecular and histological analyses. For histological analysis, the
hearts were fixed in 10% formalin, embedded in paraffin, and
sectioned at 1-mm intervals for staining. A single myocytes was
measured using images captured from hematoxylin and eosin
(H&E)–stained sections. For digital measurements of cardiomyo-
cyte cross-sectional areas (CSAs), 150 cells per genotype were
traced using Image Pro Plus (version 6.0, Media Cybernetics,
USA). The cardiac collagen volume was calculated as the ratio of
the sum of the total collagen area to the sum of the total collagen
and no collagen areas in the entire visual field of the section as
determined by picrosirius red (PSR) staining.
Echocardiography
Transthoracic echocardiography was performed using My-
labTM30CV (ESAOTE S.p.A.) with a 10-MHz linear array
ultrasound transducer before and 28 days after surgery. Measure-
ments were made by an observer blinded to the experimental
group. The chamber diameters of left ventricular (LV) were
measured at end-systole (LVESD) and end-diastole (LVEDD).
Fractional shortening (FS) and the ejection fraction (EF) were
calculated as previously described [7].
Hemodynamic Measurements
Hemodynamic measurements were obtained 28 days after AB
using a 1.4-French high-fidelity catheter (SPR-839, Millar
Instruments, Houston, TX, USA), as described previously [7]. In
short, the catheter was inserted into the right carotid artery and
advanced into the left ventricle after the animals were anesthetized
to acquire signals. After having been stabilized for 15 minutes, the
signals were continuously recorded using a Millar Pressure-
Volume System (MPVS-400, Millar Instruments, Houston, TX,
USA). PVAN software (Millar Instruments, USA) was used for the
subsequent analysis of the pressure-volume loops (PV-loop).
Quantitative Real-time RT-PCR
Real-time PCR was performed to quantify relative transcript
levels in various groups. cDNA was reverse transcribed using oligo
(dT) primers with the Advantage RT-for-PCR Kit (BD Bioscienc-
es). A real-time Roche LightCycler PCR system was used to run
PCR reactions with the SYBR Green PCR Master Mix (Applied
Biosystems) The real-time PCR results from each primer pair were
normalized to those of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) gene expression and were compared across conditions.
The primer sequences used for RT-PCR are shown in Table 1.
Protein Analyses
Total protein samples were extracted from left ventricles,
subjected to SDS–PAGE, and then eletrotransferred to nitrocel-
lulose membranes (#IPFL00010, Millipore). The Western blots
were scanned with a two-color infrared imaging system (Odyssey,
LI-COR). The GAPDH protein was used as the endogenous
control. Antibodies against the following proteins were purchased
from Cell Signaling Technology: p-MEK1/2 (#9154), T-MEK1/
2( #9122), p-ERK1/2 (#4370), T-ERK1/2 (#4695), p-p38
(#4511), T-p38 (#9212), p-JNK1/2 (#4668), T-JNK 1/
2(#9258), p-Akt (#4060), T-Akt (#4691), p-GSK3b (#9322),
T-GSK3b (#9315), p-mTOR (#2974), T-mTOR (#2972), and
GAPDH (#2118). The antibody for ELTD1 (sc-46947) was
purchased from Santa Cruz Biotechnology.
Statistical Methods
Results are presented as the mean 6 SEM. Statistical
comparisons were performed using SPSS (Statistical Package for
the Social Sciences) 17.0 software with ANOVA either alone or
followed by Tukey’s multiple-comparison test. Student’s t-tests
were used to compare means between two groups. P,0.05 was
considered statistically significant.
Results
ELTD1 Protein Levels Decrease in the Ventricles of
Patients with End Stage Heart Failure
We examined ELTD1 expression in human ventricular samples
from patients undergoing a heart transplant and from healthy
donors. Ventricular tissue from failing hearts exhibited a 2- to 3-
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normal donors (Figure 1A).
ELTD1 Gene Expression in Mice Ventricles before and
after AB
By assessing the expression pattern in various tissues, we found a
high protein level of ELTD1 in the heart of C57BL/6 mice
Table 1. A list of the primers used in this study.
Gene Name Forward (59–39) Reverse(59–39)
ELTD1 GGACCAGTTACCGACAAATCACA GATGAGGATAGCAAGGGACCAAT
a-MHC GTCCAAGTTCCGCAAGGT AGGGTCTGCTGGAGAGGTTA
b-MHC CTTCACGGGCACCCTTGGA ACCTGCTAGACCACCTGGAG
Anp ACCTGCACCACCTGGAGGAG CCTTGGCTGTTATCTTCGGTACCG
Bnp GAGGTCACTCCTATCCTCTGG GCCATTTCCTCCGACTTTTCTC
Serca2a CATTTGCATTGCAGTCTGGAT CTTTGCCATCCTACGAGTTCC
Acta1 GTGAGATTGTGCGCGACATC GGCAACGGAAACGCTCATT
Tgf-b1 ATCCTGTCCAAACTAAGGCTCG ACCTCTTTAGCATAGTAGTCCGC
Tgf-b2 TCGACATGGATCAGTTTATGCG CCCTGGTACTGTTGTAGATGGA
Col1a1 CCTCAA GGG CTC CAA CGA G TCA ATC ACT GTC TTG CCC CA
Col3a1 ACGTAGATGAATTGGGATGCAG GGGTTGGGGCAGTCTAGTC
Fibronectin CCGGTGGCTGTCAGTCAGA CCGTTCCCACTGCTGATTTATC
Ctgf TGACCCCTGCGACCCACA TACACCGACCCACCGAAGACACAG
Mmp-2 CTTTGCCATCCTACGAGTTCC CCATCAAACGGGTATCCATCTC
Mmp-9 CGGACCCGAAGCGGACAT GGGGCACCATTTGAGTTT
doi:10.1371/journal.pone.0035779.t001
Figure 1. ELTD1 expression in normal and hypertrophied ventricles. A, Representative and statistical data of western blotting for protein
levels of ELTD1 with glyceraldehyde phosphate dehydrogenase (GAPDH) as loading control (n=4). *P,0.05 vs. normal donators. Left, representative
blots. Right, quantitative results. B, Western blotting for levels of ELTD1 in mice at different tissue indicated (n=4). C, Real-time PCR for ELTD1 and
heart weight/body weight (HW/BW) in WT control mice after AB at time points indicated (n=6). Data represent as mean6SEM. Up, ratios indicate
mRNA levels normalized to GAPDH. #P,0.01 vs. the sham values.
doi:10.1371/journal.pone.0035779.g001
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real-time PCR using samples from ventricles collected 7, 14, 28,
and 56 days post AB or immediately after sham surgery. There is a
trend of increase in heart mass during that time (Figure 1C), and
the wall thickness and chamber diameter increase correspondingly
(data not shown). The levels of ELTD1 mRNA reached a
maximum at 7 days after AB and then decreased (Figure 1C).
Effect of ELTD1 Deficiency on Cardiac Hypertrophy
We measured the heart weight (HW), lung weight (LW), body
weight (BW), and tibia length (TL) at 28 days after surgery. In the
sham operation group, the ratios of the heart weight to body
weight (HW/BW) or to tibia length (HW/TL) were not different
between the KO and WT mice. AB induced a significant increase
in HW/BW and HW/TL in both WT and KO mice, and the
increase was more pronounced in KO mice than in WT mice
(Figure 2B). Morphometric assessment of H&E-stained LV
sections revealed that the CSA tended to be larger in KO mice
than in WT mice after AB (Figure 2B). Echocardiography
confirmed left ventricular hypertrophy in the KO mice, as
measured by the left ventricle posterior wall thickness (LVPWT)
and interventricular septal thickness at end-diastole (IVSD). The
wall thickness was similar in sham-operated KO and WT mice.
AB significantly increased the LVPWT and IVSD in both WT and
KO mice. ELTD1 deficiency augmented the increases in the
LVPWD and IVSD after AB (Figure 2C). Expression of the
hypertrophy genes, atrial natriuretic peptide (Anp), brain natri-
uretic peptide (Bnp), a-myosin heavy chain (a-MHC), b-MHC,
actin a1 skeletal muscle (Acta1) and sarco/endoplasmic reticulum
Ca2+-transport ATPase2a (Serca2a) correlated with the above-
described results. Anp, Bnp, a-MHC, and Acta1 were strongly
upregulated after 28 days of AB in WT mice. This up-regulation
was paralleled by a strong reduction in b-MHC and Serca2a
expression, and these changes were even evident in KO mice in
response to AB (Figure 2C).
LV Function and Chamber Diameter
To estimate the cardiac function and chamber diameter,
echocardiography and PV loop measurements were performed
before mice were euthanized 28 days after the operations. As
shown in Table 2, the chamber diameter and LV function
parameters did not differ between sham-operated WT and KO
mice. The LV chamber was enlarged after AB as indexed by
LVEDD, LVESD, and the end-diastolic and end-systolic volumes
(ESV and EDV, respectively) and was increased even more in KO
mice than in WT mice. Accordingly, the end-systolic and end-
diastolic pressures (ESP and EDP, respectively) were higher in KO
mice than in WT mice after AB. Indeed, AB significantly impaired
cardiac function as evidenced by the markedly reduced dP/dtmax
and dP/dtmin as compared to sham-operation (Table 2). ELTD1
deficiency aggravated the depression in the systolic function (dP/
dtmax, EF, FS, cardiac output and stroke volume) after pressure
overload, and similar results were observed for the diastolic
function (Tau_w and dP/dtmin) and ventricular afterload
(indexed by Ea, arterial elastance) (Table 2). These effects were
associated with an increase in the wet lung weight (LW), and
increases in the wet LW divided by the body weight or the tibia
length indicated more pulmonary congestion in the KO mice.
ELTD1 Deficiency Exacerbates the Fibrotic Response
Induced by Pressure Overload
Fibrosis is an important aspect of cardiac hypertrophy that is
characterized by extracellular matrix (ECM) deposition and is
mediated by various cytokines [8]. In our study, PSR staining
revealed striking perivascular and interstitial fibrosis in ventricles
in response to AB, and the extent of cardiac fibrosis remarkably
increased in the KO mice (Figure 3A, B).
We tried to elucidate the underlying mechanism for exacerbated
fibrosis. The mRNA levels of pro-collagen type I a1( Col1a1), pro-
collagen type III a1( Col3a1), and fibronectin were significantly
higher in KO mice than in WT mice after AB (Figure 3C),
revealing an elevated deposition of connective tissue in the
ventricles. Furthermore, mediators of fibrosis (including trans-
forming growth factor-b1( Tgfb1), Tgfb2, and connective tissue
growth factor (Ctgf) demonstrated exaggerated responses in KO
mice relative to WT after AB, as indicated by mRNA level analysis
(Figure 3C). In contrast, the level of matrix
metalloproteinase 2(Mmp2) and Mmp9 increased similarly after
AB in both groups (Figure 3C).
Effect of ELTD1 on MAPKs and Akt Activation
MAPKs and PI3K-Akt are among the most thoroughly
characterized signaling pathways that are activated by pressure
overload and drive cardiac hypertrophy [9,10]. Therefore, we
focused our analysis following AB on defining changes in signaling
events that precede unfavorable remodeling. As shown in
Figure 4A, AB promoted the phosphorylation of MEK1/2-
ERK1/2, JNK1/2, and p38-MAPK in KO and WT mice.
Deletion of ELTD1 further increased activation of MRK1/2-
ERK1/2 and JNK1/2 after AB. Notably, the phosphorylation of
p38-MAPK was not affected by the absence of ELTD1. Our data
showed that the activation of Akt was amplified by AB, but no
difference was found between the two groups after AB (Figure 4B).
In addition, we examined the activation of the downstream
effector of Akt but found no difference in GSK3b and mTOR
phosphorylation between the two groups after AB (Figure 4B).
Discussion
Cardiac hypertrophy and subsequent heart failure are impor-
tant clinical determinants of morbidity and mortality [11]. In the
present study, we demonstrated for the first time that ELTD1
deficiency exacerbated cardiac hypertrophy and cardiac function
impairment in vivo using genetically engineered ELTD1 KO mice
in AB-induced pressure overload model.
In accordance with ELTD1’s expression in rats and humans [4],
ELTD1 is highly expressed in mouse hearts. Dilated evolution of
hypertrophic cardiomyopathy is characterized by wall thinning
and cavity dilatation. This dilated status with end stage heart
failure is one single most frequent indication for heart transplan-
tation [12], and represents decompensated remodeling of the heart
to external stimuli and mechanical stresses [13].The expression of
ELTD1 drastically changed in failing human and murine
ventricles after AB, suggesting involvement of ELTD1 in
pathological hypertrophy.
ELTD1 deficiency exacerbates maladaptive remodeling in-
duced by pressure overload. Three major sets of experimental
observations support this conclusion. First, an in vivo study
demonstrated that ablation of the ELTD1 gene leads to a striking
phenotype: an approximately 27% increase in HW/BW, a 29%
increase in CSA, and a 65% increase in fibrosis area relative to
age- and body weight-matched WT animals after AB. The
hypertrophic markers are the second line of independent evidence
supporting ELTD1’s involvement in hypertrophy. It’s commonly
accepted that there are increased expressions of Anp, Bnp, b-MHC,
Acta1, and decreased expressions of Serca2a and a-MHC in mice
subjected to AB compared to controls [1]. In this study, KO of
Augmented Cardiac Hypertrophy Lacking ELTD1
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Acta1 and decreased the expressions of Serca2a and a-MHC in mice
subjected to AB. Third, KO of ELTD1 led to severely impaired
cardiac function accompanied by greater LV dilation, as
evidenced by echocardiography and PV loop measurements.
Myocardial fibrosis and myocytes hypertrophy have been impli-
cated in increased myocardial stiffness, resulting in diastolic
dysfunction. SERCA activity not only influences the rate of
cardiac relaxation but also the amount of Ca
2+ available to
activate the next contraction [14], which might be an underlying
mechanism of the loss of function.
Cardiac fibrosis, which is result from unbalanced synthesis and
degradation of collagens or/and other ECM components, is an
important hallmark of maladaptive hypertrophy [8]. Morphology
staining of PSR exhibited enlarged collagens in the myocardium of
KO-AB mice and was further confirmed by PCR analysis of
Col1a1, Col3a1, and Fibronectin. Tgfb and its pro-fibrotic target gene
Ctgf can promote ECM production [15,16,17]. Increased synthesis
of ECM components increases the levels and activities of enzymes
(MMPs), and MMPs degrade the ECM to counterbalance the
previous ECM production [18]. This is a benignant circle. In our
study, ELTD1 deficiency magnified the function of Tgfb1 and Ctgf,
which promotes the deposition of collagen. PCR analyses of
Mmp2, 9 revealed similarly elevated mRNA levels of them in KO
and WT mice after AB. These results mean that KO of ELTD1
promoted the synthesis of collagen but did not augment the MMP
-related degradation accordingly. Thus, the mechanism of the pro-
fibrotic action of ELTD1 can be attributed both to the inhibition
of degradation and promotion of synthesis.
MAPKs and PI3K-Akt signaling were investigated in our study
to determine the possible molecular mechanisms of the pro-
hypertrophy action of ELTD1. All three types of MAPKs are
activated in response to GPCR agonists and mechanical stress; in
addition, these MAPKs are activated in pressure-overloaded
hearts and failing human hearts [19,20,21]. Activation of
ERK1/2 by MEK1/2 phosphorylation leads to two fundamental
changes [22,23]. First, the subsequent phosphorylation of
substrates may contribute to cell hypertrophy by increasing
Figure 2. The effects of ELTD1 on cardiac hypertrophy 28 days post-surgery. A, Representative gross heart, wall thickness and HE staining
in WT and KO mice B, Statistical results of the HW/BW, HW/TL and myocytes cross-sectional areas(CSA) of indicated groups(n=8 mice per group,
and the number of myocytes is 150 per group). C, Parameters of wall thickness by statistical analysis of LVPWD and IVSD (n=8). D, Analysis of Anp,
Bnp, a-MHC, b-MHC, Serca2a, and Acta1 in WT and KO mice by real-time PCR analysis (n=6). For B, C and D, Data represent as mean6SEM. *P,0.01 vs.
corresponding sham; #P,0.01 vs. WT/AB after AB.
doi:10.1371/journal.pone.0035779.g002
Table 2. Hemodynamic parameters in mice 28 days post-surgery.
Sham AB
Parameter WT(n=8) KO(n=8) WT(n=8) KO(n=8)
BW(g) 2660.64 28.0160.43 27.3560.53 26.9160.39
LW(mg) 135.463.31 131.464.06 158.565.72*{ 264.4627.74#*{
LW/BW(mg/g) 5.2260.14 4.6960.11 5.7960.16*{ 9.9161.14#*{
LW/TL(mg/mm) 7.4960.12 7.2260.20 9.0360.34*{ 14.7561.57#*{
ECHO
LVEDd(mm) 3.6360.06 3.5660.06 4.3160.04*{ 4.7860.06#*{
LVESd(mm) 2.0760.05 2.1260.05 2.9260.05*{ 3.6460.08#*{
FS (%) 43.1360.92 40.6360.67 32.3660.78*{ 23.9260.72#*{
Hemodynamics
HR (min–1) 472.6610.1 464.5613.3 455.8613.5 481.0615.2
ESP (mmHg) 101.463.7 104.264.0 149.464.3*{ 176.563.2#*{
EDP (mmHg) 12.060.8 11.761.1 16.361.0 28.963.3#*{
ESV (ml) 15.060.8 13.561.0 19.960.6*{ 24.361.0#*{
EDV (ml) 29.261.1 29.160.5 32.660.3*{ 36.460.7#*{
Systolic function
dP/dtmax (mmHg/s) 9856.66471.4 9439.76398.4 8130.66400.3 7327.46463.8#*{
Ea (mmHg/ml) 5.460.3 5.860.5 12.360.6*{ 26.965.4#*{
EF (%) 54.961.4 52.563.5 39.362.1*{ 21.262.3#*{
CO (ml/min) 9022.36366.6 8426.76656.0 6177.66223.6*{ 3465.86481.6#*{
Stroke volume (ml) 19.060.5 18.761.7 13.760.8*{ 7.461.1#*{
Diastolic function
dP/dtmin (mmHg/s) 29075.46355.3 29431.56289.4 28478.66161.3*{ 25530.66347.7#*{
Tau_w(ms) 6.060.3 6.160.4 9.261.5*{ 13.761.0#*{
HR, heart rate; ESP, end-systolic pressure; EDP, end-diastolic pressure; ESV, end-systolic volume; EDV, end-diastolic volume; Ea, arterial elastance; EF, ejection fraction;
CO, cardiac output; dp/dtmax, maximal rate of pressure development; dp/dtmin, maximal rate of pressure decay; Tau_w, time constant of isovolumic pressure decay.
*P,0.05 vs. WT/sham; {P,0.05vs.KO/sham; #P,0.05 vs. WT/AB after AB.
doi:10.1371/journal.pone.0035779.t002
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Second, auto-phosphorylation of ERK1/2 results in nuclear
translocation, allowing ERK1/2 to phosphorylate nuclear targets,
which in turn promotes the transcription of hypertrophic genes, as
shown by biopsies and a transgenic mouse model [23]. Both these
processes may contribute to the maladaptive phenotype associated
with pathological hypertrophic responses. Various groups have
suggested that JNK is an important regulator of pathological
hypertrophy. However, different studies have reported that the
inactivation of JNK induced by the loss of functional MEK4
(upstream of JNK) led to attenuated or enhanced hypertrophy in
pressure-overloaded models [25,26]. JNK is also considered to be
involved in the increased expression of ANP, TGFb, Col1a1, and
Col3a1during cardiac hypertrophy [27]. According to our study,
JNK, ERK1/2, and MEK1/2, the upstream activator of ERK1/
2, were activated after pressure overload, and the KO of ELTD
enhanced the increased phosphorylation of MEK-ERK1/2 and
JNK after AB. Activation of p38 led to increased expression of the
fetal gene program, substantial induction of interstitial fibrosis, and
the loss of contractility [28]. The results of many p38 studies
appear to be contradictory: the lack of expression of expression of
p38a or its upstream regulators MEK3 and MEK6 in a transgenic
model led to a significant increase in heart size; whereas, negative
expression of p38b led to a lack of cardiac hypertrophy but
Figure 3. Increased fibrosis in ELTD1 2/2 mice. A and B, PSR staining and quantitative fibrotic area measurements. Data represent as
mean6SEM (n=8). C RT-PCR analyses of Tgfb1, Tgfb2, Cola1, Co3a1, Ctgf, Mmp2, and Mmp9 mRNA levels 28 days after surgeries. GAPDH was used as
the sample loading control. (n=6) *P,0.01 vs. corresponding sham; #P,0.01 vs. WT/AB after AB.
doi:10.1371/journal.pone.0035779.g003
Figure 4. Effect of ELTD1 on MAPKs and PI3K –Akt signaling pathway. A, Western blots of MEK1/2, ERK1/2, p38, and JNK phosphorylation
and their total protein levels 28 days after surgery in WT and KO mice. GAPDH was used as the sample loading control. (n=6). Up, representative
blots. Down, quantitative results. B, Western blots of Akt,GSK3b, and mTOR phosphorylation and their total protein levels 28 days after surgery.
GAPDH was used as the sample loading control (n=6). Up, representative blots. Down, quantitative results. For A and B, Data represent as the means
6 SEM *P,0.01 vs. corresponding sham; #P,0.01 vs. WT/AB after AB.
doi:10.1371/journal.pone.0035779.g004
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important role of p38 in pressure overload-induced remodeling.
We found increased phosphorylation of p38 in the AB group
relative to the sham-operated group, in agreement with Sari et al.
[31] and Cai et al. [32]. We did not explore the activation of
different isoforms, and the phosphorylation of different p38
isoforms seems to be influenced by race and time [33]. No
difference in p38 phosphorylation was found in ELTD1 KO mice
relative to WT mice in our research. The PI3K (p110a)-Akt
pathway has been demonstrated by a genetic mouse model to play
a critical role in regulating cardiac hypertrophy. Although PI3K-
Akt is thought to regulate physiological hypertrophy [18],
sustained or marked activation of Akt alters the expression profile
to that typical of a pathological state [34]. We found activated
phosphorylation of Akt, GSK3b and mTOR in the AB group
relative to the sham-operated group, but no difference between the
KO and WT mice. Our results suggest that ELTD1 promotes
cardiac hypertrophy through MEK-ERK1/2 and JNK signaling
rather than through PI3K-Akt signaling. However, further
experiments are needed to determine whether ELTD1 interferes
with MAPKs and Akt signaling in the same way in response to
stimulus other than pressure overload, and to understand the exact
molecular connection by which ELTD1 regulates the ERK and
JNK pathways.
In conclusion, the findings of the present study show a key role
for ELTD1 in regulating the pathological hypertrophy of the
heart, likely through its activating effects on the downstream
MER1/2-ERK1/2 and JNK signaling cascades. These results
provide new insight into the pathogenesis of cardiac remodeling.
However, additional studies are needed to test whether modifica-
tion of ELTD1 function might improve the clinical outcome in
cases of human cardiac hypertrophy or other cardiac diseases.
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